FW Thorpe: Record H1 Figures Can’t Disguise Slowing Growth And Elevated 22x Multiple

16 March 2018
By Maynard Paton

Update on FW Thorpe (TFW).

Event: Interim results for the six months to 31 December 2017 published 15 March 2018

Summary: These first-half figures actually set new H1 records, but they also confirmed TFW’s good run of double-digit profit growth will pause during 2018. Pressure on prices for tunnel lighting was cited as one reason for the pedestrian performance. Should revenue and profit continue to plateau, the elevated share price — rated at 22x my earnings guess — may be at risk of a de-rating. Still, the lighting specialist remains a very respectable business, and continues to be led by directors that think long term. I continue to hold.

Read more

Tasty: Phew! Not Heading For Bankruptcy Just Yet As £4m Property Proceeds And £1m Underlying Profit Compare To £8m Market Cap

13 March 2018
By Maynard Paton

Update on Tasty (TAST).

Event: Preliminary results for the 52 weeks to 31 December 2017 published 13 March 2018

Summary: Phew! I had thought TAST’s plunging share price was signalling these results would be accompanied by an emergency equity placing. As it turns out, the beleaguered restaurant chain continues to report a profit and has surprised me by raising £4m — equivalent to half of its market cap — from two property transactions. Furthermore, management now has a proper turnaround plan in place, the second half showed a few glimmers of hope while the upside could be considerable if a recovery ever occurs. I have bought more shares, both before and after these results.

Read more

Getech: 17-Month Results Provide Further Hope Of A Profit Rebound And Decent Share-Price Upside

02 March 2018
By Maynard Paton

Update on Getech (GTC).

Event: Final results for the seventeen months to 31 December 2017 published 28 February 2018.

Summary: A change of year end, various exceptional items, the effect of an acquisition and the company’s own ‘cost base’ definition meant studying these numbers was not straightforward. However, it was clear the geoscience software specialist has returned to profit, while it was also obvious the new boss remains confident about the group’s competitive attractions. Looking ahead, I am still hoping some encouraging revenue talk alongside tight cost controls could one day lead to much higher earnings and decent share-price upside. I continue to hold.

Read more

Tristel: H1 Results Boast 24% Profit Jump Before North American Costs As EPA Decision Now Set For 16 April

23 February 2018
By Maynard Paton

Update on Tristel (TSTL).

Event: Interim results and shareholder presentation for the six months to 31 December 2017 published 20 February 2018

Summary: These first-half figures were slightly better than I had expected, with December’s AGM statement having downplayed the group’s underlying progress. Welcome revenue advances — both in the UK and abroad — were delivered by TSTL’s main disinfectant products, while adjusted profit would have soared 24% were it not for the costs of entering North America. Sadly it remains anyone’s guess as to when those costs will eventually see any payback. Nonetheless, the first North American milestone is looming — an EPA product approval decision is expected on 16 April, and the share price is optimistic. I continue to hold.

Read more

City Of London Investment: Market Gains Deliver Best-Ever H1 As Increased Dividend Supports 6% Yield

19 January 2018
By Maynard Paton

Update on City of London Investment (CLIG).

Event: Trading update and shareholder presentation/summary results for the six months ending 31 December 2017 published 17 January 2018.

Summary: Favourable market movements helped CLIG report its best-ever first-half figures, with revenue, profit, net cash and the dividend all moving higher. However, the finer details showed the emerging-market fund manager struggling to capture new clients as its main strategy under-performed. Meanwhile, fee rates are still being chipped away and staff costs keep on climbing. The shares may look under-appreciated on a P/E of 10 and yield of 6%, but sadly a re-rating does not appear imminent. I continue to hold. 

Read more

My Portfolio: Year In Review 2017

01 January 2018
By Maynard Paton

Happy New Year!

I trust you have enjoyed the festive break and are now raring to do battle with the market for another twelve months!

This first Blog post of 2018 provides a ‘year in review’ of my current portfolio holdings. I recap how each of the underlying businesses performed during 2017, as well as provide a few remarks about valuation.

Read more

Daejan: NAV Creeps To New £103 Per Share High And I Now Wonder Whether I Should Buy Once More

29 November 2017
By Maynard Paton

Update on Daejan (DJAN).

Event: Interim results for the six months to 30 September 2017 published 29 November 2017

Summary: From what I could tell from the chairman’s 216-word update, DJAN has had to work hard of late to achieve somewhat modest progress. Currency movements and Brexit apparently kept a lid on this H1 performance, although NAV still managed to creep to a £103 per share all-time high. Dull updates from low-profile businesses often cause share prices to stagnate, and so I’m not too surprised the property group’s discount to book has widened since I first bought during 2015. I now wonder whether I should buy once again. I continue to hold.

Read more

Mountview Estates: NAV Reaches Fresh £89 Per Share High Despite Weakest H1 For 4 Years

23 November 2017
By Maynard Paton

Update on Mountview Estates (MTVW).

Event: Interim results for the six months to 30 September 2017 published 23 November 2017

Summary: It took MTVW’s chief exec just 265 words to describe the group’s weakest first-half performance for four years. Still, the nature of this property-trading firm means earnings can be somewhat variable from time to time. What is important, though, is that net asset value improved once again to a fresh high while debt continues to be reduced to a new low. My sums point to a possible NAV of £209 per share based on the firm’s long-term margin. I continue to hold.

Read more

Record: Another Frustrating RNS That Leaves The Stock’s 5% Yield As The Main Highlight

20 November 2017
By Maynard Paton

Update on Record (REC).

Event: Interim results and shareholder presentation for the six months to 30 September 2017 published 17 November 2017

Summary: This was another frustrating RNS from the specialist currency manager. The cost base has ‘inevitably’ increased, yet revenue and client numbers remain stagnant and — as usual — there’s no real sign of the business enjoying an upturn anytime soon. At least REC continues to generate cash, retains a robust cash pile and distributes a healthy dividend. The yield is 5%, which is not too bad in the current market. I continue to hold.

Read more

Castings: H1 Figures Just About Acceptable As Profit Per Tonne Reaches New £322 High

10 November 2017
By Maynard Paton

Update on Castings (CGS).

Event: Interim results for the six months to 30 September 2017 published 10 November 2017

Summary: Last month’s statement concerning a review of CGS’s machining division had already braced me for worrying news. In the circumstances, this RNS was not too bad. Sure, the machining division has reported a loss and will cut back on certain projects. However, CGS’s main foundry operation appears to be performing very satisfactorily, with profit per tonne reaching a new high. I continue to hold. 

Read more

World Careers Network: FY 2017 Figures Show Revenue And Cash At All-Time Highs, But Earnings Will Remain Depressed Until At Least 2019

03 November 2017
By Maynard Paton

Update on World Careers Network (WOR).

Event: Preliminary results for the twelve months to 31 July 2017 published 02 November 2017

Summary: These figures from the recruitment software developer were never going to be great. The overriding theme of the last three years — greater marketing and product investment — once again hit earnings and will continue to do so throughout 2018. The statement talked of some client-fee reductions, too. Still, at least overall revenue and the hefty cash position have both advanced to new all-time highs. Exactly when a profit revival will occur remains anyone’s guess — but I am hopeful the chief exec/71% shareholder will one day oversee a recovery. I continue to hold.

Read more

Getech: 2017 Results Spotlight Product Attractions And Recovery Potential From £9m Market Cap

31 October 2017
By Maynard Paton

Update on Getech (GTC).

Event: Interim results for the twelve months to 31 July 2017 published 31 October 2017

Summary: These results were never going to show a major turnaround, but glimmers of hope continue to emerge at the geoscience software specialist. In particular, a new chief exec has cut costs, reorganised the firm and spotlighted some of the company’s product attractions. True, minimal earnings are likely during the short term. But with the upbeat stock market making obvious buying opportunities hard to find, I am beginning to warm to GTC’s recovery potential. I continue to hold.

Read more

System1: H1 Profit Slumps 70% But Finer Details Provide Hope For Shareholders

27 October 2017
By Maynard Paton

Update on System1 (SYS1).

Event: Interim results and shareholder presentation for the six months to 30 September 2017 published 27 October 2017

Summary: The marketing-services group had already alerted investors to these disappointing figures. However, the setback was explained honestly by management and I note 50% of the business continues to grow at a fair rate. So everything does not appear completely lost just yet. That said, adopting the tag of industry ‘pioneer’ will always court competition and it seems rivals have tempted some customers away. The share price has been thumped since the summer, but is now looking quite interesting. I continue to hold.

Read more

Tristel: I Had To Delve Deep Into These 2017 Results After Underlying Revenue Gained Only 7%

25 October 2017
By Maynard Paton

Update on Tristel (TSTL).

Event: Final results and shareholder presentation for the year to 30 June 2017 published 19 October 2017

Summary: July’s trading statement from this medical disinfectants specialist had already signalled these record results. However, the update showed underlying revenue growth of just 7%, with the UK up 3% and overseas up 10%. I’ve therefore had to delve deep into the numbers to ensure TSTL’s main products continue to sell relatively well. At least the company’s accounts and recent acquisition showed more obvious appeal. I must confess, I am nervous comparing the share-price valuation against the medium-term expansion potential, especially with the prospect of sizeable North American revenue as distant as ever. I continue to hold.

Read more

Bioventix: Outstanding 2017 Results But Cagey Troponin Remarks May Leave 29x P/E Rather Exposed

16 October 2017
By Maynard Paton

Update on Bioventix (BVXP).

Event: Preliminary results for the year to 30 June 2017 published 16 October 2017

Summary: The antibody specialist delivered another outstanding set of results, as astonishing margins, robust cash production and magnificent equity returns once again underlined the group’s wonderful economics. However, matters were tempered somewhat by management remarks about the immediate revenue potential of a new product. It could mean progress during 2018 won’t be very impressive, which may leave the current 29x multiple rather exposed. I’m hoping things work out for the best, and continue to hold.

Read more